Background and aims: Cancer continues to be a significant source of both illness
and death on a global scale, traditional medicinal plants continue to serve as a
fundamental resource of natural bioactive compounds as an alternative source of
remedies. Although there have been numerous studies on the therapeutic role of
Phoenix dactylifera, the study of the role of peptides has not been thoroughly
investigated. This study aimed to investigate the anticancer activity of lectin
peptides from P. dactylifera using in silico and in vivo analysis.
Methods: Different computational tools were used to extract and predict
anticancer peptides from the true lectins of P. dactylifera. Nine peptides that
are bioactiv... More
Background and aims: Cancer continues to be a significant source of both illness
and death on a global scale, traditional medicinal plants continue to serve as a
fundamental resource of natural bioactive compounds as an alternative source of
remedies. Although there have been numerous studies on the therapeutic role of
Phoenix dactylifera, the study of the role of peptides has not been thoroughly
investigated. This study aimed to investigate the anticancer activity of lectin
peptides from P. dactylifera using in silico and in vivo analysis.
Methods: Different computational tools were used to extract and predict
anticancer peptides from the true lectins of P. dactylifera. Nine peptides that
are bioactive substances have been investigated for their anticancer activity
against MCF-7 and T47D (two forms of breast cancer). To counteract the
unfavorable effects of mitotane, the most potent peptides (U3 and U7) were
combined with it and assessed for anticancer activity against MCF-7 and HepG2.
Results: In silico analysis revealed that nine peptides were predicted with
anticancer activity. In cell lines, the lowest IC50 values were measured in
U3 and U7 against MCF-7 and T47D cells. U3 or U7 in combination with
mitotane demonstrated the lowest IC50 against MCF-7 and HepG2. The
maximum level of cell proliferation inhibition was 22% when U3 (500 µg/mL)
and 25 µg/mL mitotane were combined, compared to 41% when 25 µg/mL
mitotane was used alone. When mitotane and U3 or U7 were combined, it
was shown that these bioactive substances worked synergistically with
mitotane to lessen its negative effects. The combination of peptides and
mitotane could be regarded as an efficient chemotherapeutic medication
having these bioactive properties for treating a variety of tumors while
enhancing the reduction of side effects.
